Compounds > lutetium
Page last updated: 2024-08-22

lutetium and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

lutetium has been researched along with 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid in 67 studies

Research

Studies (67)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (25.37)29.6817
2010's40 (59.70)24.3611
2020's10 (14.93)2.80

Authors

AuthorsStudies
Chen, S; Goldenberg, DM; Govindan, SV; Griffiths, GL; Hansen, HJ; Reed, L; Richel, H; Stein, R1
Cutler, CS; Hoffman, T; Hu, F; Jurisson, SS; Sieckman, G; Volkert, WA1
Brechbiel, MW; Chappell, LL; Dadachova, E; Garmestani, K; Ma, D; Milenic, DE; Schlom, J; Yordanov, A1
Bernard, BF; Breeman, WA; de Jong, M; Erion, JL; Krenning, EP; van der Wansem, K; van Gameren, A; Visser, TJ1
Breeman, WA; De Jong, M; Erion, JL; Krenning, EP; Visser, TJ1
Beitzel, MP; Brechbiel, MW; Chappell, LL; Garmestani, K; Ma, D; Milenic, DE; Venditto, V1
Mårtensson, L; Nilsson, R; Ohlsson, T; Senter, P; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z1
Grünberg, J; Knogler, K; Novak-Hofer, I; Schubiger, PA; Zimmermann, K1
Eisenhut, M; Maecke, HR; Reubi, JC; Schuhmacher, J; Waser, B; Wild, D; Zhang, H1
Mather, SJ; Sosabowski, JK1
Miao, Y; Quinn, TP; Shelton, T1
Baum, RP; Müller, D; Senftleben, S; Wehrmann, C; Zachert, C1
Breeman, WA; Elst, LV; Hermann, P; Kolar, ZI; Kubícek, V; Lukes, I; Muller, RN; Peters, JA; Vitha, T; Wolterbeek, HT1
Caldeira Filho, JS; Colturato, MT; Couto, RM; de Araújo, EB; Mengatti, J; Muramoto, E; Nagamati, LT; Pujatti, PB; Silva, CP1
Chen, J; Fani, M; Forrer, F; Lohri, A; Maecke, HR; Moldenhauer, G; Müller-Brand, J; Powell, P1
Babaei, MH; Daha, FJ; Rajabi, H; Rasaneh, S; Salouti, M1
Archimandritis, SC; Bouziotis, P; Garnuszek, P; Karczmarczyk, U; Koumarianou, E; Maurin, M; Mikołajczak, R; Pawlak, D; Zikos, X1
Banerjee, S; Chakraborty, S; Das, T; Sarma, HD; Venakatesh, M1
Bigner, DD; Hens, M; Vaidyanathan, G; Zalutsky, MR; Zhao, XG1
Cescato, R; Fani, M; Maecke, HR; Mueller, A; Nicolas, G; Reubi, JC; Rink, HR; Tamma, ML1
Bergmann, R; Pietzsch, HJ; Schiller, E; Wunderlich, G1
Bao, A; Cheng, Z; Cochran, JR; Culter, CS; Jiang, L; Kimura, RH; Li, P; Liu, H; Miao, Z1
Decristoforo, C; Helbok, A; Kabasakal, L; Kremser, L; Ocak, M; Ozsoy, Y; von Guggenberg, E1
Babaei, MH; Rajabi, H; Rasaee, Mj; Salouti, M1
Cescato, R; Fani, M; Reubi, JC; Waser, B1
Eriksson, SE; Nilsson, R; Ohlsson, T; Tennvall, J1
Frangioni, JV; Orcutt, KD; Rhoden, JJ; Ruiz-Yi, B; Wittrup, KD1
Kjaer, A; Madsen, J; Persson, M; Ploug, M; Rasmussen, P1
Baek, HS; Choi, SJ; Choi, SM; Hong, YD; Kim, JJ; Lim, JC1
Müller, C; Schibli, R; Struthers, H; Winiger, C; Zhernosekov, K1
Breeman, WA; Chan, HS; de Blois, E; de Zanger, R; Konijnenberg, M1
Campana, B; Forrer, F; Lohri, A; Maecke, H; Mueller-Brand, J; Oechslin-Oberholzer, C1
Janssen, HM; Lub, J; Renart Verkerk, P; Robillard, MS; Rossin, R; Ten Hoeve, W; van den Bosch, SM1
Guo, H; Miao, Y1
Abrahmsen, L; Ekblad, C; Frejd, FY; Jonsson, A; Lindborg, M; Lundqvist, H; Orlova, A; Rosik, D; Tolmachev, V1
Engelbogen, N; Havlíčková, J; Herdtweck, E; Hermann, P; Kapp, TG; Kessler, H; Notni, J; Šimeček, J; Wester, HJ1
Chakraborty, S; Pillai, MR; Sarma, HD; Vimalnath, KV1
Adam, MJ; Cawthray, JF; Lewis, JS; Orvig, C; Price, EW; Ramogida, CF; Ramos, N; Zeglis, BM1
Bunka, M; Fischer, C; Müller, C; Reber, J; Schibli, R; Türler, A; Zhernosekov, K1
Balkin, ER; Jia, F; Lewis, MR; Liu, D; Miller, WH; Ruthengael, VC; Shaffer, SM1
Huxol, E; Mindt, TL; Valverde, IE1
Abbas, N; Bruland, ØS; Dahle, J; Larsen, RH; Repetto-Llamazares, A1
Cho, EH; Choi, SM; Kim, JJ; Lee, SY; Lim, JC; Nam, SS; Park, SH; Park, UJ1
Chakraborty, S; Das, T; Pillai, AM1
Breeman, WA; Chan, HS; de Blois, E; de Zanger, RM1
Afshar-Oromieh, A; Bauder-Wüst, U; Benešová, M; Eder, M; Haberkorn, U; Kopka, K; Kratochwil, C; Mier, W; Schäfer, M1
Baran, P; Garnuszek, P; Maurin, M; Mikołajczak, R; Pawlak, D1
Mascarin, A; Mindt, TL; Valverde, IE1
Alwarda, R; Cai, Z; Jeong, JJ; Lu, Y; Pignol, JP; Reilly, RM; Tong, L; Winnik, MA; Yook, S1
Chen, J; Liu, F; Si, L; Wang, Y; Wu, L; Wu, Y; Xia, Q; Xiao, S; Xu, H; Yang, Z; Yao, T; Zhang, B; Zhang, L; Zhang, Z; Zhou, D; Zhu, H1
Bal, A; Bhusari, P; Dhawan, DK; Mittal, BR; Parmar, M; Shukla, J; Singh, G; Vatsa, R1
Amirdhanayagam, J; Banerjee, S; Das, T; Guleria, M; Kumar, C; Sarma, HD1
Asti, M; Capponi, PC; Dreger, T; Esposizione, LR; Fioroni, F; Formisano, D; Grassi, E; Iori, M; Pitzschler, R; Rubagotti, S; Seemann, J; Versari, A1
Bhusari, P; Kumar, R; Mittal, BR; Parihar, AS; Shukla, J; Sood, A1
Berntzen, DT; Løitegård, T; Thiis-Evensen, E1
Escudero-Castellanos, A; Ferro-Flores, G; Isaac-Olivé, K; Luna-Gutiérrez, M; Morales-Ávila, E; Ocampo-García, B; Santos-Cuevas, C1
Bodei, L; Gönen, M; Krebs, S; Lewis, JS; Lohrmann, C; Lyashchenko, SK; O'Donoghue, JA; Pandit-Taskar, N; Raj, N; Reidy-Lagunes, D; Staton, KD; Weber, WA1
Castel, H; Desrues, L; Gandolfo, P; Hörmann, AA; Klingler, M; Rangger, C; von Guggenberg, E1
Battan, S; Bracke, A; De Loose, J; De Meester, I; Moon, ES; Rösch, F; Van der Veken, P; Van Rymenant, Y1
Arroub, K; Drzezga, A; Kaur, J; Mathur, S; Schomäcker, K1
Keam, SJ1
Jacene, H; Ravi, P; Shah, H; Sonpavde, G1
Agrawal, S; Amiri-Kordestani, L; Chen, W; Chiang, K; Fallah, J; Fiero, MH; Fotenos, A; Gittleman, H; Ibrahim, A; John, C; Kluetz, PG; Niu, G; Pazdur, R; Pierce, WF; Ricks, TK; Subramaniam, S; Suzman, DL; Tang, S; Wang, M1
Chen, ZS; Fang, GC; Han, CH; Liu, X; Lu, H; Shi, ZD1
Abedi, SM; Hosseinimehr, SJ; Khorramimoghaddam, A; Molavipordanjani, S; Mousavi, T; Talebpour Amiri, F1
Azorín-Vega, EP; de la Fuente-Mendoza, JE; Mendoza-Nava, HJ; Rodríguez-Dorantes, M; Rodríguez-Martínez, G1

Reviews

4 review(s) available for lutetium and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

ArticleYear
Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:23

    Topics: Chelating Agents; Chromatography, High Pressure Liquid; Excipients; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Methionine; Pentetic Acid; Peptides; Protein Stability; Radioactivity; Radiometry; Radiopharmaceuticals

2012
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Molecular diagnosis & therapy, 2022, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome

2022
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
    Expert review of anticancer therapy, 2022, Volume: 22, Issue:11

    Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2022
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
    Drugs of today (Barcelona, Spain : 1998), 2023, Volume: 59, Issue:1

    Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2023

Trials

5 trial(s) available for lutetium and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

ArticleYear
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Pilot Projects; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes

2009
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2012, Volume: 56, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Rituximab; Treatment Outcome

2012
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    International journal of cancer, 2017, 02-15, Volume: 140, Issue:4

    Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Feasibility Studies; Female; Genes, erbB-2; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Mastectomy; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Pilot Projects; Radioimmunotherapy; Radioisotopes; Receptor, ErbB-2; Single Photon Emission Computed Tomography Computed Tomography; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tamoxifen; Tissue Distribution; Trastuzumab

2017
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23

    Topics: Adult; Aged; Chelating Agents; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Prognosis; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult

2019
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 05-01, Volume: 29, Issue:9

    Topics: Adult; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Receptors, Androgen; Taxoids; Treatment Outcome

2023

Other Studies

58 other study(ies) available for lutetium and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

ArticleYear
Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Female; Glycoproteins; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Lung Neoplasms; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy; Radioisotopes; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes

2001
Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).
    Nuclear medicine and biology, 2002, Volume: 29, Issue:4

    Topics: Animals; Bombesin; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Metabolic Clearance Rate; Metals, Rare Earth; Mice; Peptide Fragments; Promethium; Prostatic Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Samarium; Sensitivity and Specificity; Tissue Distribution

2002
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Nuclear medicine and biology, 2002, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Aniline Compounds; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Isothiocyanates; Lutetium; Mice; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Whole-Body Counting; Xenograft Model Antitumor Assays

2002
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:2

    Topics: Animals; Bone Marrow; Femur; Heterocyclic Compounds, 1-Ring; Injections, Intravenous; Kidney; Lutetium; Male; Octreotide; Organ Specificity; Organometallic Compounds; Pentetic Acid; Radiation-Protective Agents; Radioisotopes; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution

2003
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:6

    Topics: Binding, Competitive; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Isotope Labeling; Kinetics; Ligands; Lutetium; Peptides; Radioisotopes; Yttrium Radioisotopes

2003
Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Nuclear medicine and biology, 2003, Volume: 30, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Chelating Agents; Colonic Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Metabolic Clearance Rate; Mice; Organ Specificity; Radioimmunoassay; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution

2003
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2

    Topics: Animals; Antibodies, Monoclonal; Biotin; Body Weight; Brain; Chelating Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Leukocytes; Lutetium; Maximum Tolerated Dose; Platelet Count; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Yttrium Radioisotopes

2005
Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Nuclear medicine and biology, 2006, Volume: 33, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Cell Line; Chelating Agents; Drug Evaluation, Preclinical; Female; Glycosylation; Heterocyclic Compounds, 1-Ring; Humans; Liver; Lutetium; Metabolic Clearance Rate; Mice; Mice, Nude; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Radioisotopes; Radiopharmaceuticals

2006
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:8

    Topics: Animals; Bombesin; Cell Line, Tumor; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Neoplasm Transplantation; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Receptors, Bombesin

2007
Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes.
    Nature protocols, 2006, Volume: 1, Issue:2

    Topics: Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Isotope Labeling; Lutetium; Metals; Molecular Structure; Peptides; Yttrium Radioisotopes

2006
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:3

    Topics: alpha-MSH; Animals; Arginine; Chelating Agents; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Kidney; Lutetium; Melanoma; Mice; Radiography; Radioisotopes; Survival Analysis

2007
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:3

    Topics: Adult; Aged; Bone Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Radiotherapy; Radiotherapy Dosage; Receptors, Peptide; Tomography, X-Ray Computed

2007
Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy.
    Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3

    Topics: Amides; Animals; Bone and Bones; Chelating Agents; Diphosphonates; Gadolinium; Heterocyclic Compounds, 1-Ring; Lanthanum; Ligands; Lutetium; Male; Radioisotopes; Radionuclide Imaging; Rats; Rats, Inbred Lew; Structure-Activity Relationship; Tissue Distribution

2008
A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2009, Volume: 67, Issue:2

    Topics: Animals; Chelating Agents; Heterocyclic Compounds, 1-Ring; Iodine Radioisotopes; Lutetium; Mice; Neuroendocrine Tumors; Pharmacokinetics; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Tissue Distribution

2009
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
    Nuclear medicine and biology, 2009, Volume: 36, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Buffers; Cell Line, Tumor; Cell Survival; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Quality Control; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Staining and Labeling; Trastuzumab

2009
Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Nuclear medicine and biology, 2009, Volume: 36, Issue:6

    Topics: Animals; Biological Transport; Bombesin; Cell Line, Tumor; Cell Survival; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Male; Mice; Radiopharmaceuticals; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes

2009
A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
    Nuclear medicine and biology, 2010, Volume: 37, Issue:5

    Topics: Animals; Chelating Agents; Cross-Linking Reagents; Female; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Neoplasms; Porphyrins; Radioisotopes; Radionuclide Imaging; Treatment Outcome

2010
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Nuclear medicine and biology, 2010, Volume: 37, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; ErbB Receptors; Flow Cytometry; Glioma; Heterocyclic Compounds, 1-Ring; Humans; Isothiocyanates; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Stereoisomerism; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2010
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:11

    Topics: Animals; Calcium; Cell Transformation, Neoplastic; CHO Cells; Cricetinae; Cricetulus; Drug Design; Enzyme Stability; Female; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; HEK293 Cells; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Mice; Neuroendocrine Tumors; Positron-Emission Tomography; Protein Transport; Radioactive Tracers; Radiography; Receptors, Somatostatin; Somatostatin; Structure-Activity Relationship; Tomography, Emission-Computed, Single-Photon

2010
Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).
    Nuclear medicine and biology, 2010, Volume: 37, Issue:8

    Topics: Animals; Drug Stability; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kinetics; Lutetium; Male; Microspheres; Rats; Rats, Wistar; Serum Albumin; Yttrium Radioisotopes

2010
Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
    European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:4

    Topics: Adult; Amino Acid Sequence; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Cystine-Knot Miniproteins; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Integrins; Lutetium; Male; Mice; Models, Molecular; Molecular Sequence Data; Platelet Membrane Glycoproteins; Protein Conformation; Radiation Dosage; Radiochemistry; Radioisotopes; Radiotherapy

2011
Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
    Nuclear medicine and biology, 2011, Volume: 38, Issue:2

    Topics: Amino Acid Sequence; Animals; Binding Sites; Biological Assay; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Female; Gastrins; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Mice; Mice, Inbred BALB C; Peptide Hydrolases; Protein Stability; Radioisotopes; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Extracts

2011
Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer.
    Nuclear medicine and biology, 2011, Volume: 38, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Mice; Mice, Inbred BALB C; Quality Control; Radioimmunodetection; Radioimmunotherapy; Radioisotopes

2011
Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:12

    Topics: Amino Acid Sequence; Autoradiography; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Neoplasms; Oligopeptides; Protein Binding; Radioisotopes; Receptors, Somatostatin

2011
Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Chelating Agents; Colonic Neoplasms; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds, 1-Ring; Immunoenzyme Techniques; Lutetium; Male; Radioimmunotherapy; Radioisotopes; Rats; Rats, Inbred BN

2012
Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:6

    Topics: Animals; Antibodies, Bispecific; Carcinoembryonic Antigen; Cells, Cultured; Chelating Agents; Coordination Complexes; Haptens; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Lutetium; Mice; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous

2012
New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Nuclear medicine and biology, 2012, Volume: 39, Issue:7

    Topics: Animals; Beta Particles; Cell Transformation, Neoplastic; Colorectal Neoplasms; Dideoxynucleosides; Female; Heterocyclic Compounds, 1-Ring; HT29 Cells; Humans; Lutetium; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Oligopeptides; Positron-Emission Tomography; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Substrate Specificity

2012
Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
    Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:8

    Topics: alpha-MSH; Animals; Disease Models, Animal; Drug Delivery Systems; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligopeptides; Radioisotopes; Radiopharmaceuticals; Receptor, Melanocortin, Type 1; Tissue Distribution

2012
DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:1

    Topics: Albumins; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Folic Acid; Heterocyclic Compounds, 1-Ring; Humans; KB Cells; Lutetium; Mice; Molecular Targeted Therapy; Multimodal Imaging; Positron-Emission Tomography; Radioisotopes; Tomography, X-Ray Computed

2013
Evaluation of strained alkynes for Cu-free click reaction in live mice.
    Nuclear medicine and biology, 2013, Volume: 40, Issue:3

    Topics: Alkynes; Animals; Antibodies, Monoclonal, Murine-Derived; Azides; Click Chemistry; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Radioisotopes; Rituximab

2013
Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.
    Bioorganic & medicinal chemistry letters, 2013, Apr-15, Volume: 23, Issue:8

    Topics: alpha-MSH; Animals; Cell Line, Tumor; Coordination Complexes; Drug Delivery Systems; Heterocyclic Compounds, 1-Ring; Lactams; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution

2013
Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6

    Topics: Albumins; Animals; Binding Sites; Cell Line, Tumor; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Mice; Ovarian Neoplasms; Protein Structure, Tertiary; Protein Transport; Radioisotopes; Radiometry; Receptor, ErbB-2; Recombinant Fusion Proteins; Substrate Specificity; Tissue Distribution

2013
A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric bioconjugates.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2013, Jun-10, Volume: 19, Issue:24

    Topics: Chelating Agents; Copper; Cyclams; Gadolinium; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Integrin alphaVbeta3; Ligands; Lutetium; Molecular Structure; Peptides; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Radiopharmaceuticals; Thermodynamics; Yttrium

2013
Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Nuclear medicine and biology, 2013, Volume: 40, Issue:7

    Topics: Animals; Dimerization; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Melanoma; Mice; Octanols; Peptides, Cyclic; Radiation Dosage; Radioactive Tracers; Radiochemistry; Radioisotopes; Water

2013
H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
    Journal of the American Chemical Society, 2013, Aug-28, Volume: 135, Issue:34

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chelating Agents; Ethylamines; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Lutetium; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Radiopharmaceuticals; Tissue Distribution; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:12

    Topics: Animals; Beta Particles; Chelating Agents; Cyclotrons; Feasibility Studies; Female; Folic Acid; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; KB Cells; Lutetium; Mice; Positron-Emission Tomography; Radiochemistry; Radioisotopes; Scandium

2013
Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
    Nuclear medicine and biology, 2014, Volume: 41, Issue:1

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Genes, bcl-2; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lutetium; Lymphoma, B-Cell; Mice; Oligoribonucleotides, Antisense; Peptide Nucleic Acids; Peptides, Cyclic; Proto-Oncogene Mas; Radioisotopes; Radiometry; Tissue Distribution

2014
Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting.
    Journal of labelled compounds & radiopharmaceuticals, 2014, Volume: 57, Issue:4

    Topics: Amino Acid Sequence; Bombesin; Cell Line, Tumor; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Male; Peptide Fragments; Peptidomimetics; Prostatic Neoplasms; Proteolysis; Radioisotopes; Tomography, Emission-Computed, Single-Photon; Triazoles

2014
Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunotoxins; Iodine Radioisotopes; Lutetium; Lymphoma, B-Cell; Mice; Mice, Nude; Molecular Targeted Therapy; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Tetraspanins; Tissue Distribution; Xenograft Model Antitumor Assays

2014
Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Nuclear medicine and biology, 2015, Volume: 42, Issue:3

    Topics: Aminobenzoates; Animals; Bombesin; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glycosylation; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2015
Estimation of specific activity of 177Lu by 'saturation assay' principle using DOTA as ligand.
    Current radiopharmaceuticals, 2015, Volume: 8, Issue:2

    Topics: Chelating Agents; Heterocyclic Compounds, 1-Ring; Ligands; Lutetium; Peptides; Radioisotopes

2015
Alternative method to determine Specific Activity of (177)Lu by HPLC.
    Current radiopharmaceuticals, 2015, Volume: 8, Issue:2

    Topics: Chromatography, High Pressure Liquid; Heterocyclic Compounds, 1-Ring; Lutetium; Octreotide; Organometallic Compounds; Peptides; Radiochemistry; Radioisotopes; Receptors, Peptide

2015
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:6

    Topics: Animals; Antigens, Surface; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Peptides; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution

2015
The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
    Nuclear medicine review. Central & Eastern Europe, 2015, Volume: 18, Issue:2

    Topics: Chemical Phenomena; Chemistry Techniques, Synthetic; Drug Stability; Gallium Radioisotopes; Gastrins; Heterocyclic Compounds, 1-Ring; Isotope Labeling; Lutetium; Yttrium Radioisotopes

2015
Structure-Activity Relationship Studies of Amino Acid Substitutions in Radiolabeled Neurotensin Conjugates.
    ChemMedChem, 2016, Jan-05, Volume: 11, Issue:1

    Topics: Amino Acid Substitution; Heterocyclic Compounds, 1-Ring; HT29 Cells; Humans; Lutetium; Molecular Structure; Neurotensin; Radioisotopes; Radiopharmaceuticals; Structure-Activity Relationship

2016
Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
    Biomacromolecules, 2016, Apr-11, Volume: 17, Issue:4

    Topics: Animals; Beta Particles; Breast Neoplasms; Female; Gold; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Metal Nanoparticles; Mice; Mice, Nude; Nanomedicine; Polymers; Radioisotopes; Radiopharmaceuticals; Sulfhydryl Compounds

2016
Synthesis of Site-Specific Radiolabeled Antibodies for Radioimmunotherapy via Genetic Code Expansion.
    Bioconjugate chemistry, 2016, Oct-19, Volume: 27, Issue:10

    Topics: Animals; Benzoxazines; Chelating Agents; Chemistry Techniques, Synthetic; Copper Radioisotopes; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Isotope Labeling; Lutetium; Mice, SCID; Positron-Emission Tomography; Radioimmunotherapy; Radioisotopes; Rituximab

2016
Preparation of clinical-scale
    Journal of labelled compounds & radiopharmaceuticals, 2017, 05-15, Volume: 60, Issue:5

    Topics: Animals; Cell Line, Tumor; Drug Compounding; Drug Stability; Freeze Drying; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Mice; Radioisotopes; Rituximab; Tissue Distribution

2017
Labelling of
    Contrast media & molecular imaging, 2017, Volume: 2017

    Topics: Automation; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Radiation Exposure; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Yttrium Radioisotopes

2017
Novel use of
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:10

    Topics: Carcinoma, Papillary; Female; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Lutetium; Middle Aged; Oligopeptides; Radioisotopes; Radionuclide Imaging; Thyroglobulin; Thyroid Cancer, Papillary; Thyroid Neoplasms

2018
The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
    Annals of nuclear medicine, 2019, Volume: 33, Issue:3

    Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden

2019
Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
    Nuclear medicine communications, 2019, Volume: 40, Issue:3

    Topics: Animals; Antigens, Surface; Bombesin; Cell Line, Tumor; Chemistry Techniques, Synthetic; Dimerization; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lysine; Male; Mice; Prostatic Neoplasms; Radiochemistry; Radioisotopes; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2019
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
    Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23

    Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Drug Stability; Female; Gastrins; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Lutetium; Mice, Inbred BALB C; Proline; Protein Binding; Radioisotopes; Radiopharmaceuticals; Rats; Receptor, Cholecystokinin B

2020
In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA
    Molecules (Basel, Switzerland), 2021, Jun-08, Volume: 26, Issue:12

    Topics: Acetates; Azepines; Endopeptidases; Fibroblasts; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Membrane Proteins; Positron Emission Tomography Computed Tomography; Quinine; Radioisotopes; Radiopharmaceuticals; Scandium; Serine Endopeptidases

2021
Synthesis, proteolytic stability, and
    Organic & biomolecular chemistry, 2021, 11-25, Volume: 19, Issue:45

    Topics: Amino Acid Sequence; HEK293 Cells; Heterocyclic Compounds, 1-Ring; Humans; In Vitro Techniques; Lutetium; MCF-7 Cells; Peptides; Proteolysis; Radiopharmaceuticals

2021
Lutetium lu 177 vipivotide tetraxetan (Pluvicto) for prostate cancer.
    The Medical letter on drugs and therapeutics, 2022, 12-12, Volume: 64, Issue:1665

    Topics: Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostatic Neoplasms

2022
The preclinical study of
    Annals of nuclear medicine, 2023, Volume: 37, Issue:7

    Topics: Animals; Cell Line, Tumor; Humans; Lutetium; Mice; Mice, Nude; Neoplasms; Radiopharmaceuticals; Tissue Distribution

2023
Estimation of the relative biological effectiveness (RBE) of the Lu-DOTA-iPSMA177 ra
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2023, Volume: 202

    Topics: Humans; Lutetium; Male; Radioisotopes; Radiopharmaceuticals; Relative Biological Effectiveness

2023